Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

KALA BIO, Inc.

Contributing Author

Recent Articles by KALA BIO, Inc.

May-07
KALA BIO Announces Reverse Stock Split KALA -27.80% GlobeNewswire
Apr-21
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine KALA -7.45% GlobeNewswire
Apr-01
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities KALA -5.83% GlobeNewswire
Mar-30
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live KALA GlobeNewswire
Mar-18
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate KALA GlobeNewswire
Mar-11
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates KALA +24.16% GlobeNewswire
Mar-04
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform "Researgency" KALA GlobeNewswire
Jan-05
KALA BIO Settles Approximately $10.6 million of Debt KALA KALA +6.90% GlobeNewswire
Dec-05
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules KALA -6.64% KALA -6.86% GlobeNewswire
Dec-04
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules KALA GlobeNewswire
Dec-01
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar KALA +37.67% GlobeNewswire
Sep-29
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint KALA -89.27% GlobeNewswire
Sep-03
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference KALA +23.13% GlobeNewswire
Sep-02
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director KALA +8.65% GlobeNewswire
Aug-08
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update KALA GlobeNewswire
Aug-06
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference KALA GlobeNewswire
Jul-09
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA +22.09% GlobeNewswire
Jul-07
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) KALA GlobeNewswire
May-29
KALA BIO to Present at Jefferies Global Healthcare Conference KALA GlobeNewswire
May-14
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update KALA -6.03% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)